Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising

  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. Mensah K, Gaur R, Connarn J, et al. CC-99677: A novel, oral, selective MK2 inhibitor with sustainable multi-cytokine inhibition for the treatment of ankylosing spondylitis and other inflammatory diseases [abstract: 0489]. Arthritis Rheumatol. 2021 Oct; 73(suppl 10).

Related Articles

    Remembering Etanercept & the Advent of the Biologic Era

    As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

    Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

    ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…